CL2017002960A1 - Compuesto para la profilaxis o el tratamiento de daño al órgano - Google Patents

Compuesto para la profilaxis o el tratamiento de daño al órgano

Info

Publication number
CL2017002960A1
CL2017002960A1 CL2017002960A CL2017002960A CL2017002960A1 CL 2017002960 A1 CL2017002960 A1 CL 2017002960A1 CL 2017002960 A CL2017002960 A CL 2017002960A CL 2017002960 A CL2017002960 A CL 2017002960A CL 2017002960 A1 CL2017002960 A1 CL 2017002960A1
Authority
CL
Chile
Prior art keywords
treatment
damage
compound
prophylaxis
organ damage
Prior art date
Application number
CL2017002960A
Other languages
English (en)
Inventor
Der Graaf Adrianus Cornelis Van
Robert Henk Henning
Leo Edwin Deelman
Gerrit Jan Willem Euverink
Original Assignee
Sulfateq Bv
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=56014996&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=CL2017002960(A1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by Sulfateq Bv filed Critical Sulfateq Bv
Publication of CL2017002960A1 publication Critical patent/CL2017002960A1/es

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D311/00—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings
    • C07D311/02—Heterocyclic compounds containing six-membered rings having one oxygen atom as the only hetero atom, condensed with other rings ortho- or peri-condensed with carbocyclic rings or ring systems
    • C07D311/04—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring
    • C07D311/58—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4
    • C07D311/70—Benzo[b]pyrans, not hydrogenated in the carbocyclic ring other than with oxygen or sulphur atoms in position 2 or 4 with two hydrocarbon radicals attached in position 2 and elements other than carbon and hydrogen in position 6
    • C07D311/72—3,4-Dihydro derivatives having in position 2 at least one methyl radical and in position 6 one oxygen atom, e.g. tocopherols
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/335—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin
    • A61K31/35—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom
    • A61K31/352—Heterocyclic compounds having oxygen as the only ring hetero atom, e.g. fungichromin having six-membered rings with one oxygen as the only ring hetero atom condensed with carbocyclic rings, e.g. methantheline 
    • A61K31/353—3,4-Dihydrobenzopyrans, e.g. chroman, catechin
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P13/00—Drugs for disorders of the urinary system
    • A61P13/12—Drugs for disorders of the urinary system of the kidneys
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P39/00—General protective or antinoxious agents
    • A61P39/06—Free radical scavengers or antioxidants
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D405/00—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/06—Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings linked by a carbon chain containing only aliphatic carbon atoms

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Animal Behavior & Ethology (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • General Chemical & Material Sciences (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Urology & Nephrology (AREA)
  • Biochemistry (AREA)
  • Toxicology (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)

Abstract

<p>LA PRESENTE INVENCIÓN SE REFIERE A COMPUESTOS PARA LA PROFILAXIS O EL TRATAMIENTO DEL DAÑO AL ÓRGANO MEDIANTE LA RESTAURACIÓN DE LA FUNCIÓN ENDOTELIAL Y/O LA INHIBICIÓN DE LA PRODUCCIÓN DE ESPECIES DE OXÍGENO REACTIVAS Y ESPECIALMENTE A COMPUESTOS PARA LA PROFILAXIS O EL TRATAMIENTO DEL DAÑO RENAL DIABÉTICO. ESPECÍFICAMENTE, LA INVENCIÓN PRESENTE RELACIONA A 6- HIDROXI-2,5,7,8-TETRAMETILCROMAN-2-IL) (PIPERAZIN-1-IL) METANONA O N, 6-DIHIDROXI-2,5,7,8-TETRAMETILCROMAN-2-CARBOXAMIDA O UNA SAL O BASE FARMACÉUTICAMENTE ACEPTABLE DE LOS MISMOS PARA EL USO EN LA PROFILAXIS O TRATAMIENTO DEL DAÑO AL ÓRGANO MEDIANTE LA RESTAURACIÓN DE LA FUNCIÓN ENDOTELIAL O LA INHIBICIÓN DE LA PRODUCCIÓN DE ESPECIES REACTIVAS DE OXÍGENO Y DAÑO ORGÁNICO A LOS RIÑONES DIABÉTICOS.</p>
CL2017002960A 2015-05-22 2017-11-21 Compuesto para la profilaxis o el tratamiento de daño al órgano CL2017002960A1 (es)

Applications Claiming Priority (1)

Application Number Priority Date Filing Date Title
NL2014843 2015-05-22

Publications (1)

Publication Number Publication Date
CL2017002960A1 true CL2017002960A1 (es) 2018-03-16

Family

ID=56014996

Family Applications (1)

Application Number Title Priority Date Filing Date
CL2017002960A CL2017002960A1 (es) 2015-05-22 2017-11-21 Compuesto para la profilaxis o el tratamiento de daño al órgano

Country Status (15)

Country Link
US (2) US10676452B2 (es)
EP (1) EP3297625B1 (es)
JP (2) JP6967456B2 (es)
CN (1) CN107660148B (es)
AU (1) AU2016268975B2 (es)
BR (1) BR112017024854B1 (es)
CA (1) CA2986300C (es)
CL (1) CL2017002960A1 (es)
DK (1) DK3297625T3 (es)
ES (1) ES2927699T3 (es)
HU (1) HUE060167T2 (es)
MX (1) MX388654B (es)
PL (1) PL3297625T3 (es)
PT (1) PT3297625T (es)
WO (1) WO2016188766A1 (es)

Families Citing this family (7)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
ES2927699T3 (es) * 2015-05-22 2022-11-10 Sulfateq Bv Compuesto para la profilaxis o el tratamiento de nefropatía diabética o enfermedad renal diabética
EP3672592A1 (en) 2017-08-25 2020-07-01 Sulfateq B.V. 6-chromanol derivatives for use as a medicament
ES3013118T3 (en) 2017-08-25 2025-04-11 Sulfateq Bv Medicaments for the treatment of vasoconstriction related diseases or disorders
CA3079483A1 (en) * 2017-11-22 2019-05-31 Khondrion Ip B.V. Compounds as mpges-1 inhibitors
NL2025730B1 (en) * 2020-06-02 2022-01-20 Sulfateq Bv Compounds for treatment of sepsis
NL2026511B1 (en) * 2020-09-21 2022-05-24 Sulfateq Bv Compounds for treatment of heart failure

Family Cites Families (17)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4681890A (en) 1984-10-30 1987-07-21 Kuraray Co., Ltd. 3,4-dihydrobenzopyran compounds and pharmaceutical composition containing the same
EP0202580B1 (en) 1985-05-13 1990-03-28 Kuraray Co., Ltd. 3,4-dihydrobenzopyran derivatives
CA1338012C (en) 1987-04-27 1996-01-30 John Michael Mccall Pharmaceutically active amines
US5266709A (en) 1989-03-13 1993-11-30 Ono Pharmaceutical Co., Ltd. Benzopyran derivatives
US5506245A (en) * 1992-10-12 1996-04-09 Adir Et Compagnie Thiazolidinedione compounds
US5457109A (en) 1993-09-15 1995-10-10 Warner-Lambert Company Use of thiazolidinedione derivatives and related antihyperglycemic agents in the treatment of disease states at risk for progressing to noninsulin-dependent diabetes mellitus
FR2756284B1 (fr) 1996-11-26 2000-04-28 Adir Nouveaux derives du benzopyrane, leur procede de preparation et les compositions pharmaceutiques qui les contiennent
US6335445B1 (en) * 1997-03-24 2002-01-01 Societe De Conseils De Recherches Et D'applications Scientifiques (S.C.R.A.S.) Derivatives of 2-(iminomethyl)amino-phenyl, their preparation, their use as medicaments and the pharmaceutical compositions containing them
EP0894089B9 (en) 1997-05-02 2003-04-02 Dr. Reddy's Laboratories Ltd. Novel heterocyclic compounds having antidiabetic, hypolipidaemic, antihypertensive properties, process for their preparation and pharmaceutical compositions containing them
AR019190A1 (es) * 1998-07-08 2001-12-26 Sod Conseils Rech Applic Derivados de 2-aminopiridinas, productos intermedios para su preparacion, medicamentos y composiciones farmaceuticas que los contienen y su uso para preparar medicamentos
US6768008B2 (en) 2000-04-24 2004-07-27 Aryx Therapeutics Materials and methods for the treatment of diabetes, hyperlipidemia, hypercholesterolemia, and atherosclerosis
WO2004076437A1 (en) 2003-02-26 2004-09-10 Shanghai Institute Of Materia Medica, Chinese Academy Of Sciences Benzopyran compounds, process for preparing the same and their use
EP1650206A4 (en) * 2003-08-01 2006-12-20 Nippon Soda Co PHENYLAZOLE COMPOUNDS, PROCESS FOR THEIR PRODUCTION AND ANTIOXIDANTS
WO2005033092A1 (en) * 2003-09-19 2005-04-14 Galileo Pharmaceuticals, Inc. Chroman derivatives
HUE033757T2 (en) * 2012-07-12 2017-12-28 Khondrion Ip B V Chromanyl derivatives for treating mitochondrial disease
NL2010010C2 (en) * 2012-12-19 2014-06-23 Sulfateq B V Compounds for protection of cells.
ES2927699T3 (es) * 2015-05-22 2022-11-10 Sulfateq Bv Compuesto para la profilaxis o el tratamiento de nefropatía diabética o enfermedad renal diabética

Also Published As

Publication number Publication date
MX2017014912A (es) 2018-06-13
AU2016268975A1 (en) 2017-11-30
CA2986300A1 (en) 2016-12-01
PT3297625T (pt) 2022-09-27
US10676452B2 (en) 2020-06-09
WO2016188766A1 (en) 2016-12-01
DK3297625T3 (da) 2022-10-17
AU2016268975B2 (en) 2021-08-12
CA2986300C (en) 2024-02-20
US20210024485A1 (en) 2021-01-28
BR112017024854A2 (pt) 2018-08-14
HUE060167T2 (hu) 2023-02-28
EP3297625A1 (en) 2018-03-28
PL3297625T3 (pl) 2022-11-14
CN107660148B (zh) 2021-03-09
ES2927699T3 (es) 2022-11-10
JP6967456B2 (ja) 2021-11-17
JP2021120381A (ja) 2021-08-19
MX388654B (es) 2025-03-20
BR112017024854B1 (pt) 2023-12-26
US20180170892A1 (en) 2018-06-21
CN107660148A (zh) 2018-02-02
JP2018520106A (ja) 2018-07-26
EP3297625B1 (en) 2022-07-06

Similar Documents

Publication Publication Date Title
CL2017002960A1 (es) Compuesto para la profilaxis o el tratamiento de daño al órgano
DOP2020000102A (es) Compuestos útiles para inhibir a cdk7
CL2018000318A1 (es) Compuestos derivados de piridinona, inhibidores de bromodominio; composición farmacéutica que los comprende; y su uso en el tratamiento de enfermedades del cáncer. (solicitud divisional 201600925)
CO2018009275A2 (es) Derivados pirrolidina espiro-condensados como inhibidores de enzimas desubiquitinantes (dub)
CO2019005165A2 (es) Compuesto de piridona como inhibidor de c-met
CL2013002417A1 (es) Compuestos derivados de fluoropiridinona; composición farmacéutica que los comprende; y su uso en el tratamiento de infecciones bacterianas.
CL2017001209A1 (es) Inhibidor de cinasa aurora a
CR20150416A (es) Inhibidores de cdc7
CL2017000379A1 (es) Compuestos de pirrolopirimidina usados como agonistas del receptor de tipo toll. 7 (tlr7)
AR098274A1 (es) Inhibidor de grelina o-acil transferasa
MX2016006199A (es) Inhibidores de replicacion del virus de influenza.
MX2016015434A (es) Combinaciones farmaceuticas para tratar cancer.
AR102973A1 (es) Uso del compuesto 3,5-dihidroxi-4-isopropil-trans-estilbeno para la preparación de una composición farmacéutica, dicho compuesto y composición farmacéutica que lo comprende
SV2018005702A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
CR20160016A (es) Pirazolpiridinas sustituidas
AR112144A1 (es) Compuestos para el tratamiento del sarcoma
DOP2019000100A (es) Derivados de naftiridinona y su uso en el tratamiento de la arritmia
AR105821A1 (es) COMPUESTOS ÚTILES PARA INHIBIR ROR-g-T
CL2020002139A1 (es) Compuestos de sulfonimidoilpurinona 7-sustituidos y sus derivados para el tratamiento y prevención del cáncer de hígado.
SV2018005701A (es) Compuestos de 1,3,4-tiadiazol y su uso en el tratamiento del cancer
MX2017006110A (es) Carboxamidas de quinolina para usarse en el tratamiento de leucemia.
DOP2019000194A (es) Derivados de pirrolotriazina como inhibidor de cinasas
AR109328A1 (es) Derivado de triazolopirazinona útil como un inhibidor de pde1 humana
SV2016005310A (es) Derivados de diheterociclo enlazado a cicloalquilo
AR088735A1 (es) Compuestos de tienopirimidina que son inhibidores de canal de potasio